Clinical Trial

Canagliflozin in Advanced Renal Disease With MRI Endpoints

Study acronym: CARe-MRI
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II, proof of concept, placebo-controlled, randomized clinical trial, assessing the effect of canagliflozin on cardiac structure and function in patients with advanced renal disease, including those on maintenance dialysis. Our primary aim is to determine the effect of canagliflozin on cardiac structure and function in patients with advanced chronic kidney disease (CKD), compared with placebo. We hypothesize that canagliflozin will improve left ventricular (LV) hypertrophy in patients with advanced CKD. Our secondary aims are to describe the effect of canagliflozin on other cardiac magnetic resonance imaging parameters and surrogate markers of efficacy in this population.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-12-13; most recent amendment 2025-12-04.
Status change: Not Yet Recruiting → Recruiting 2024-05-31
Trial Details
NCT Number NCT06182839
Lead Sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators: Heart and Stroke Foundation of Canada
Conditions ESRD, CKD Stage 4, CKD Stage 5
Enrollment 92 participants
Start Date 2024-05-01
Primary Completion 2028-03-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-08